A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.

Yuan-Di C HalvorsenJohn Paul LockJuan Pablo FriasFrancisco José TinahonesDominik DahlAnnie L ConeryMason W Freeman

Published in: Diabetes, obesity & metabolism (2022)

Bexagliflozin was noninferior to glimepiride in lowering HbA1c, was superior to glimepiride for decreases in body mass and SBP, and was associated with significantly fewer hypoglycaemic events than glimepiride. A favourable effect on eGFR was observed.

Keyphrases

randomized controlled trial
study protocol
small cell lung cancer
double blind
placebo controlled
clinical trial
epidermal growth factor receptor
systematic review
combination therapy
phase ii
phase iii
open label